Perspectives on plasma biomarkers for point-of-care diagnostics in Alzheimer's disease: Insights into 2D-BioPAD.

IF 2.8 Q2 NEUROSCIENCES

Journal of Alzheimer's disease reports Pub Date : 2026-04-01 eCollection Date: 2026-01-01 DOI:10.1177/25424823261437790

Angeliki Koukoura, Kyriaki Antonopoulou, Apostolos C Tsolakis, Alina Solomon, Magda Tsolaki, Lutz Froelich, Anthoula Tsolaki, Eirini Papadaki, Efstathios Vassiliadis, Gitte Juel Holst

{"title":"Perspectives on plasma biomarkers for point-of-care diagnostics in Alzheimer's disease: Insights into 2D-BioPAD.","authors":"Angeliki Koukoura, Kyriaki Antonopoulou, Apostolos C Tsolakis, Alina Solomon, Magda Tsolaki, Lutz Froelich, Anthoula Tsolaki, Eirini Papadaki, Efstathios Vassiliadis, Gitte Juel Holst","doi":"10.1177/25424823261437790","DOIUrl":null,"url":null,"abstract":"We investigated the potential of plasma biomarkers for point-of-care in vitro diagnostics in Alzheimer's disease by collecting insights from 99 stakeholders primarily from Greece, including patients, caregivers, healthcare professionals, and researchers. Data from an online survey was analyzed using descriptive statistics and thematic analysis. Key biomarkers reported by participants included Aβ40, Aβ42, pTau181, pTau217, and neurofilament light chain. While biomarkers were recognized for their value in prognosis, diagnosis, and monitoring, most participants were unfamiliar with point-of-care in vitro diagnostics. Major concerns regarding implementation included cost, reimbursement, and accessibility, underscoring the need for more feasible and context-appropriate diagnostic solutions.","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261437790"},"PeriodicalIF":2.8000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710411/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's disease reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25424823261437790","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

We investigated the potential of plasma biomarkers for point-of-care in vitro diagnostics in Alzheimer's disease by collecting insights from 99 stakeholders primarily from Greece, including patients, caregivers, healthcare professionals, and researchers. Data from an online survey was analyzed using descriptive statistics and thematic analysis. Key biomarkers reported by participants included Aβ₄₀, Aβ₄₂, pTau181, pTau217, and neurofilament light chain. While biomarkers were recognized for their value in prognosis, diagnosis, and monitoring, most participants were unfamiliar with point-of-care in vitro diagnostics. Major concerns regarding implementation included cost, reimbursement, and accessibility, underscoring the need for more feasible and context-appropriate diagnostic solutions.

查看原文本刊更多论文

血浆生物标志物在阿尔茨海默病即时诊断中的前景：对2D-BioPAD的见解。

我们通过收集主要来自希腊的99个利益相关者（包括患者、护理人员、医疗保健专业人员和研究人员）的见解，研究了血浆生物标志物在阿尔茨海默病现场体外诊断中的潜力。使用描述性统计和专题分析对在线调查数据进行分析。参与者报告的关键生物标志物包括a - β40、a - β42、pTau181、pTau217和神经丝轻链。虽然生物标志物在预后、诊断和监测方面的价值得到了认可，但大多数参与者不熟悉即时体外诊断。关于实施的主要问题包括成本、报销和可及性，强调需要更可行和适合具体情况的诊断解决方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Alzheimer's disease reports

CiteScore

2.80

自引率

0.00%

发文量